{
    "clinical_study": {
        "@rank": "164976", 
        "arm_group": {
            "arm_group_label": "Low Level Light Therapy (LLLT)", 
            "arm_group_type": "Experimental", 
            "description": "LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face,  Left face,  Left neck,  Midline neck, Right neck\nDose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2\nRoute: Extraoral\nTotal Treatment Time (all sites) 6 min\nSchedule:  First day of conditioning through Day +20"
        }, 
        "brief_summary": {
            "textblock": "In this research study, the investigators are assessing the feasibility of providing\n      extraorally delivered low level light therapy LLLT for the prevention of oropharyngeal\n      mucositis OM in children undergoing myeloablative hematopoietic cell transplantation  HCT."
        }, 
        "brief_title": "Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Oropharyngeal Mucositis", 
            "Myeloablative Hematopoietic Cell Transplantation", 
            "Low Level Light Therapy"
        ], 
        "condition_browse": {
            "mesh_term": "Mucositis"
        }, 
        "detailed_description": {
            "textblock": "This is an open label, single treatment arm clinical pilot study evaluating the feasibility\n      of extraorally delivered low level light therapy (LLLT) for the prevention of oropharyngeal\n      mucositis (OM) in pediatric patients undergoing myeloablative hematopoietic cell\n      transplantation (HCT). Participants will be treated daily (including weekends and holidays)\n      beginning on the first day of HCT conditioning and continuing through day +20 or hospital\n      discharge if prior to day +20. Subjects will undergo formal mucositis and toxicity\n      assessments at baseline and daily from day -1 through day +20, with a final assessment on\n      the last day of treatment. There will be no further treatments or assessments beyond day\n      +20. The study will enroll a total of twelve evaluable patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to undergo myeloablative conditioning followed by autologous or allogeneic\n             hematopoietic cell transplantation at Boston Children's Hospital.\n\n          -  4 years of age to 18 years of age.\n\n          -  WHO Oral Toxicity score of 0 at baseline evaluation (first day of conditioning).\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n             (for patients under the age of 18 this applies to parent/guardian)\n\n          -  Ability to understand and/or the willingness of their parent or legally authorized\n             representative to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n          -  Treatment with oral LLLT within 4 weeks of HCT.\n\n          -  Participants may not be receiving any other agents intended for the\n             prevention/management of mucositis (including palifermin and ice chips/cryotherapy).\n\n          -  WHO \u22651 at baseline evaluation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119897", 
            "org_study_id": "13-611"
        }, 
        "intervention": {
            "arm_group_label": "Low Level Light Therapy (LLLT)", 
            "intervention_name": "Low Level Light Therapy", 
            "intervention_type": "Device", 
            "other_name": "THOR Model LX2M (THOR Photomedicine Ltd, Chesham, UK)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Oropharyngeal Mucositis", 
            "Myeloablative Hematopoietic Cell Transplantation", 
            "Low Level Light Therapy"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cduncan@partners.org", 
                    "last_name": "Christine Duncan, MD", 
                    "phone": "617-632-6255"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Boston Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Christine Duncan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nathaniel S Treister, DMD, DMSc", 
                    "phone": "617-732-6570"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Nathaniel S Treister, DMD, DMSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Christine Duncan, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation", 
        "overall_contact": {
            "email": "ntreister@partners.org", 
            "last_name": "Nathaniel Treister, DMD, DMSc", 
            "phone": "617-732-6570"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Nathaniel Treister, DMD,DMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Several measures will be collected to evaluate the overall feasibility of providing daily extraoral LLLT for children undergoing HSCT including:\nAccessibility and maneuverability of the LLLT device (transportation from storage site to hospital room, device weight)\nAdministration of LLLT (device settings, positioning of device, delivery of therapy)\nPatient tolerability (level of comfort during treatments, compliance with daily therapy\nProportion of days with therapy administered, as evidence by data submitted (goal is \u226575%)\nAbility to enroll at least 5 patients within the first 3 months (this pertains to the feasibility of study conduct, and not to the feasibility of the therapeutic approach)", 
            "measure": "The ability to maneuver and provide a new treatment for mucositis using (extraoral) LLLT", 
            "safety_issue": "No", 
            "time_frame": "20 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119897"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Nathaniel S. Treister, DMD, DMSc", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To address secondary the investigators, will calculate the following proportion: (number of times patients refused to complete one or both questionnaires) / (number of questionnaire completion timepoints), and place a 95% confidence interval on the proportion.", 
                "measure": "Patient compliance with completing questionnaires", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }, 
            {
                "description": "To address secondary aim, the investigator, will analyze the data from the WHO Oral Toxicity Scale and the ChIMES instrument using the analytic methods specifically prescribed for these standardized instruments.", 
                "measure": "WHO Oral Toxicity Scale/ChIMES Instrument", 
                "safety_issue": "Yes", 
                "time_frame": "2 Years"
            }, 
            {
                "measure": "Toxicity measured using CTC Version", 
                "safety_issue": "Yes", 
                "time_frame": "2 Years"
            }, 
            {
                "measure": "Dose-limiting toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 Years"
            }
        ], 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}